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for cancer patients in Poland? 
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Introduction. Relative 5-year cancer survival rates in Poland are around 10% lower than the average of the whole 
EU. One of the likely factors for poorer treatment outcomes in Poland may be the long times between when cancer 
is suspected to starting treatment. This study has thus aimed to determine whether the introduced oncology reforms 
have succeeded in reducing such times. 
Materials and methods. The study survey was undertaken at 6 oncological centres on patient subjects before 
(n = 1373) and after (n = 431) the oncological reform (DILO) had been introduced. Data was obtained from an in-
house devised questionnaire together with patient interview and their medical history. The following waiting times 
were estimated: A) from suspicion of cancer, (date of first doctor visit due to appearance of symptoms, screening/ 
/follow-up or prevention), to diagnosis (date of histopathological confirmation), B) from suspicion of cancer to the 
start of treatment and C) from diagnosis to starting treatment before and after the DILO reform had been introduced.
Results. The median waiting time between suspicion of cancer and treatment was 11 weeks before the DILO reform 
but was not significantly shortened after its introduction; the reduction being barely 3 days. This waiting time was 
however increased by 8 days in those patients without DILO cards. Before the DILO reform, the median time from 
diagnosis was 5.9 weeks, but was reduced by 8 days in patients bearing the DILO card and indeed increased in those 
without the DILO card by over 2 weeks. 
Conclusions. Cancer treatment waiting times in Poland is still somewhat long (over 9 weeks in most cases). Intro-
ducing the oncological reform has not significantly impacted on shortening the waiting times in cancer patients for 
receiving oncological treatment.
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Introduction
Cancer constitutes a serious health problem in Poland 
and the world. At present it is the second commonest cause 
of mortality, whilst in women aged between 30 and 69 
years it is the first [1]. Within the backdrop of the European 
Union (EU), Poland is a country with a relatively low cancer 
incidence but with a high mortality. This low incidence rate 
is likely because of incomplete reporting of new cancer 
diagnoses made to the National Tumour Registry (KRN) by 
healthcare providers. In terms of mortality rates, Poland 
occupies second from last place after Hungary. According 
to the latest analyses of EUROCARE 5, the five-year relative 
survival in Poland is around 10% lower than the EU aver-
age [2–4]. One likely reason for this may be a late detection 
169
of cancer in Poland; often already made at advanced stages. 
Another factor causing such worse outcomes in Poland, 
when compared to the EU, may be the low funding for 
medical services, resulting in reduced access to diagnostic 
and therapeutic services, thereby increasing the time for 
starting cancer treatment. Expenditure for cancer treatment 
per capita in Poland is about one third of the EU average 
(respectively 37 and 102 euros per annum). The ratio of 
mortality to morbidity is over 0.6 in Poland and it is one of 
the highest in the EU; as is also the case for Romania and 
Greece. In countries where funding for cancer treatment is 
higher, then this ratio becomes close to 0.4 [2]. The effective-
ness of a given cancer therapy is most probably affected by 
waiting time as variously supported by published studies, 
although conclusions have not always been unequivocal. 
A Dutch study [5] found that prolonging waiting time of up 
to 3 months after a diagnosis of head and neck head cancer 
reduced 5 year overall survival by 18% and significantly 
increased mortality risk after 2 months from diagnosis. A 
meta-analyses showed similar findings [6], where prolonged 
waiting times for treatment from the first signs of breast can-
cer (< 3 vs 3–6 months) reduced the 5-year survival by 5–7%.
Our study aim was to determine whether the oncologi-
cal reform introduced in Poland actually shortened the real 
waiting time for diagnoses and treatment in cancer patients.
Materials and methods
Study subjects were 1373 patients treated for can-
cer prior to the advent of the oncological cancer reform 
(22.05.2014 to 19.02.2015) and 431 cancer patients after the 
reform (from 17.11.2015 to 06.06.2016); at 6 cancer centres 
in Poland. Originally 11 cancer centres had been invited to 
participate, differing in geographic location, size, organi-
sation and financing of their medical services. Six centres 
were approved for the study, three of which are regional 
oncological centres funded by the National Health Fund 
(IA–C) and the other 3 being privately funded; of the latter, 
one centre was funded by the National Health Fund (IIA) 
and two centres were owned by an investor who covers the 
costs of medical services (IIIA–B). The study was sponsored 
by the Oncology Foundation 2025.
An in-house questionnaire was developed for the sur-
vey and such data was supplemented by patient medical 
histories. The questionnaire had been previously validated 
by a twice repeated pilot study on 50 patients before and 
after 2 weeks. Reply concordance was tested by the Cohen 
kappa coefficient.
Our study received approval from the Bioethics Com-
mission at the University of Warmia and Mazury in Olsztyn. 
All respondents agreed to participate in the study and have 
their medical records at our disposal.
The median waiting times were estimated as follows: 
A) from suspicion of cancer, (date of first doctor’s visit due to 
the appearance of abnormal symptoms suggesting cancer 
or if they are discovered whenever screening/follow-up or 
prevention tests were undergone and confirmed by tests 
after referral), to diagnosis (date of histopathological confir-
mation), B) from suspicion of cancer to the start of treatment 
and C) from diagnosis to starting treatment before and after 
the DILO reform had been launched.
From the cancer suspicion time to treatment, 112 pa-
tients were excluded from the study whilst in addition, 
474 patients were excluded from the study in the groups: 
waiting time from suspicion to diagnosis and waiting time 
from diagnosis to starting treatment (Fig. 1).
Statistical analyses
The distribution of variables was tested by the Sha-
piro-Wilk test. As aforementioned the questionnaire was 
validated using the Kappa Cohen Coefficient. Differenc-
es in subgroup ratios were tested using the c2 test. The 
Mann-Whitney U test was used for comparing waiting times 
before and after the oncological reform. Statistical signifi-
cance was assumed to be p < 0.05. Analyses were carried out 
using STATISTICA software (version 12.5) (StatSoft, Poland) 
and SPSS Statistics 23.0.
Results
There were 1266 and 426 patient subjects respectively 
in the study, (time from suspicion of cancer to starting treat-
ment), before and after the Diagnostic and Treatment of 
Cancer (DILO) reform had been introduced. For the staging 
analysis, i.e. from suspicion of cancer to diagnosis and from 
diagnosis to treatment, there were respectively 890 and 328 
patient subjects before and after the reform had been intro-
duced; Figure 1 and Table I. Upon validating the question-
naire, the replies agreed very satisfactorily (kappa: 0.81–1.00; 
p < 0.0001) when the ‘patient pathway’ was started and 
for gender and age. Good agreement was seen (kappa: 
0.61–0.80, p < 0.0001) when patients used private practice 
for diagnoses whilst moderate agreement was obtained 
(kappa: 0.41–0.60; p < 0.0001) for the date at which cancer 
was suspected. The distribution of the waiting time was 
non-parametric (p < 0.001).
The median waiting time from suspicion of cancer to 
starting treatment was 11 weeks before the oncological can-
cer reform had been launched. After the reform, this time was 
not significantly reduced in patients possessing a DILO card; 
the difference being only 3 days, p = 0.43. Nevertheless, in 
patients without a DILO card, the median waiting time be-
tween when cancer was suspected to treatment was longer 
by 8 days; p = 0.81 (Fig. 2A). The median waiting time for 
histopathological diagnosis from when cancer was suspected 
was 5.9 weeks prior to the oncological cancer reform. Within 
this period, the median duration of histopathological testing, 
as measured from the date of sample collection until the 
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results were officially reported, was 7 days. In those patients 
with a DILO card, the diagnosis time was shortened by 8 days 
(p = 0.01), whilst the duration of histopathological testing re-
mained unchanged. Patients without DILO cards however had 
an increased diagnosis time by more than 2 weeks (p = 0.03) 
and their median time of histopathological testing also in-
creased (by 2 days). The time from histopathological diagnosis 
to starting treatment had not substantially changed since the 
DILO reform was introduced (Fig. 2B).
Discussion
Guidelines and regulations in many countries are in 
place which govern patient waiting times for oncological 
treatment. In the UK, this time is legally guaranteed; the 
maximum waiting time between a GP (General Practitioner) 
visit to a specialist physician appointment is 14 days, whilst 
the duration between the diagnosis of cancer to treatment 
is 31 days. The maximum waiting time between a GP/fam-
ily doctor referral when cancer is suspected until starting 
treatment is 62 days. Similarly in Denmark, the first visit to 
an oncologist must be made within 2 weeks upon whence 
a referral is issued, (referral to a specialist electronically pro-
vided, where the patient is also invited to visit by telephone 
or electronic means), whilst oncological treatment must 
begin no later than the ensuing 2 weeks. Waiting times for 
complementary chemotherapy or radiotherapy cannot be 
more than 4 weeks from the date that the referral was re-
ceived. Very detailed recommendations are made for certain 
cancers, for example breast cancer, where the time from 
referral to imaging diagnostics and its completion cannot 
take more than 6 calendar days and that the diagnoses 
should be finished in the next 8 days, which includes his-
topathological findings. Oncological treatment must then 
begin no later than after another 13 days has elapsed; the 
total waiting time from when breast cancer is suspected to 
starting treatment is 27 days in this country. In Norway, the 
referral should reach a specialist and be considered within 
5 working days, whilst treatment of at least 80% patients 
is expected to commence within 20 working days of the 
referral. In the Czech Republic, the maximum waiting time 
for computer tomography (CT) is 3 weeks, for magnetic 
resonance (MR) 5 weeks and 6 weeks for mammography [7].
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Figure 1. Study enrolment criteria for subject patients
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Up until the 1st January 2015 in Poland, there had been 
no statutory maximum waiting time for oncological treat-
ment. The reform introduced for rapid oncological diagnosis 
and treatment presupposes certain durations in which the 
various stages of diagnostics should occur. The statutory 
maximum time for initial diagnostics is 35 days (and 28 
days from 2016) whilst the maximum time for in-depth 
diagnosis is 28 days. The time between consultation and 
starting treatment cannot exceed 14 days [8]. Nonetheless, 
the reform does not define the maximum time after a GP/ 
/family doctor referral, nor that of another specialist, be-
tween when cancer is suspected to when starting treatment. 
Most of the DILO card patients (56%) received specialist out-
patient care (Polish AOS) after cancer had been diagnosed, 
but only 14% of DILO card patients DILO remained under 
primary healthcare physicians (Polish POZ). Unfortunately 
the NFZ data on how the DILO reform is performing is as 
yet incomplete and they do not reflect the real situation of 
waiting time for the diagnosis and treatment of cancer. This 
presented study has determined the actual patient waiting 
time for diagnosis and oncological treatment in Poland, 
both before and after introducing the oncological reform, 
and can thus be used to assess how effective such actions 
undertaken by the Ministry of Health have been.
Our study has shown that the real waiting time for treat-
ment from the suspicion of cancer in Poland was, and is 
still, too long; in most patients exceeding 9 weeks, with the 
median time being about 11 weeks both before and after 
the reform. It should however be stated that when only 
DILO card data are analysed, as per the NFZ, the analogous 
median waiting time for the same respondents are 4 weeks; 
however this data is unreliable as it is solely based on the 
documentation but does not reflect the actual situation of 
the patients in reality. There are only a very few studies for 
determining the actually real waiting time for diagnosing 
and treating cancer, not only in Poland but elsewhere in the 
world. These have been attempts to analyze waiting times 
for diagnosis and treatment of patients suffering from the 
most common cancers, i.e. lung and breast cancers. A study 
from 2014 on the causes of delays in treating breast cancer 
patients (260 women from the Lublin region) demonstrated 
that the average time from the first physician visit to treat-
ment was 3.2 weeks [9]. Another study by Sawicki et al. [10] 
on 300 patients diagnosed with lung cancer from the De-
partment of Torque-Surgery in Lublin (January 2010 to 2011) 
showed that the median waiting time for treatment after the 
first physician visit was 12 weeks. In Finland, diagnosing lung 
cancer is a priority and treatment is usually given without 
undue delay. Based on the Finnish database, Salomaa et 
al.  [11] estimated that the median waiting time between 
starting treatment and the first GP visit was 10.4 weeks in 
a group of 132 patients diagnosed with lung cancer in 2001. 
Yorio et al. [12] conducted a retrospective analysis of 482 pa-
Table I. Characteristics of patient subjects before and after introducing 
the DILO oncological reform
Patient 
characteristics 
DILO reform c2 test
BEFORE AFTER
Number (%) Number (%)
1266 100 426 100
Age
≤ 65 lat 870 (69) 253 (59)
p < 0.001
> 65 lat 396 (31) 173 (41)
Gender
Women 683 (54) 179 (42)
p < 0.001
Men 583 (46) 247 (58)
Initial tumour localisation
Breast 317 (25) 64 (15)
Lung 224 (17) 73 (17)
Large intestine 164 (13) 60 (14)
Prostate gland 123 (10) 69 (16)
Head and neck 
regions




119 (9) 34 (8)
Upper gastro-
intestinal tract




40 (3) 15 (4)
Brain 35 (3) 14 (3)
Others 61 (5) 31 (7)
Reasons for starting the ‘patient pathway’
Feeling illness/ 
/lesions noticed
993 (78) 310 (73)
Screening/ 
/prevention testing
197 (16) 72 (17) p = 0.006
Follow-up testing 
at cancer clinics
76 (6) 44 (10)
Centre
IA 386 (30) 152 (36)
IB 267 (21) 101 (24)
IC 149 (12) 109 (25) p < 0.001
IIA 207 (16) 64 (15)
IIIA 134 (11) 0 (0)
IIIB 123 (10) 0 (0)
Private sector health services
Yes 281 (22) 96 (23)
No 753 (60) 330 (77) p = 0.066
No data 232 (18) 0 (0)
Starting treatment methods




604 (48) 219 (51) p = 0.004
Endocrine therapy 53 (4) 32 (8)
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tients diagnosed with stage I–III non-small cell lung cancer 
in the United States between 2000 and 2005 and showed 
an 8.4 week median time between the first imaging test 
when cancer was suspected to when the treatment started.
Our study has shown that the median waiting time from 
histopathological diagnosis to suspicion of disease was 5.9 
weeks and was decreased by around one week following the 
introduction of reforms in the DILO card bearing patients, 
but increased by more than 2 weeks in patients without this 
card. In Finland, the aforementioned Salomaa et al. [11] study 
demonstrated that the median waiting time for patients with 
lung cancer from the first GP visit to diagnosis was 52 days 
(7.4 weeks). We have shown that the median waiting time 
between starting treatment from histopathological diagnosis 
was 5.1 weeks prior to the oncological cancer reform, which 
remained substantially unchanged after the introduction 
of the DILO reform. Indeed, this median was similar to the 
statutory maximum waiting time set in the UK, at 31 days [7].
The aforementioned Yorio et al. [12] study from the USA, 
showed that the median waiting time between treatment 
and histopathological confirmation of lung cancer was 33 
days. Based on a Canadian database of over 5,000 patients 
diagnosed with lung, breast and colorectal cancer between 
1992 and 2000, the median waiting time to radiotherapy 
was defined and found to vary according to the type of 
cancer. In lung cancer, the median time from diagnosis to 
radiotherapy was 6 weeks, but it was 16 weeks for breast 
and colorectal cancers [13]. A Dutch study [5] found that 
the median waiting time of patients with head and neck 
tumours between histopathological testing to the onset 
of treatment was 37 days.
Determining the waiting time for oncological treatment 
is difficult, because defining the date of the first doctor visit 
when cancer symptoms actually appear is subjective. Also, 
the retrospective character of this study is linked to the 
already existing medical documentation of patients, some-
times unfortunately incomplete. Nevertheless, our survey is 
the largest, in terms of sample size and geographical cover-
age, of the real waiting time waiting between diagnosis of 
cancer and oncological treatment as yet undertaken so far 
in Poland. It also allows statutory public health initiatives 
to be realistically assessed for their effectiveness. Various 
studies have proved the likely impact of waiting time on 
the effectiveness of therapy and thus shortening the wait-
ing time for oncological treatment may turn out to be one 
of the factors improving survival rates for those patients 
suffering from cancer in Poland. 
Conclusions
1. The waiting time between treatment and when cancer 
is suspected in Poland was, and is still too long; in most 
patients (60%) this exceeds 9 weeks.
2. Introducing the oncological reform has not significantly 
reduced waiting times for cancer patients with cancer; 
a 3 day reduction for those with DILO cards but an 8 day 
increase for those without. 
3. The waiting time reported by the DILO card data does 
not reflect actual waiting times.
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